09:43 AM EDT, 09/24/2025 (MT Newswires) -- TG Therapeutics ( TGTX ) said Wednesday that new data from phase 3 trials assessing Briumvi showed that 89.9% of relapsing multiple sclerosis patients were free from disability progression during the sixth year of continuous treatment.

The company said 10.1% of patients had confirmed disability progression that lasted 24 weeks compared with patients who switched to Briumvi from teriflunomide.

Briumvi's overall safety profile remained consistent over six years of continuous treatment, the company added.

Price: 35.83, Change: +0.26, Percent Change: +0.73